In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-13

Study Completion Date

2024-09-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glioblastoma (GBM) is the most frequent brain tumor. Currently survival is poor and few treatments are available. Recent data show that there is no immune privilege of the central nervous system (CNS) and that GBM are invaded by effector CD8 T cells, letting us hypothesis that GBM growth is dependent of immunosurveillance.

The aim of this study is to better understand the antitumor immune response against GBM to unravel new effectors and immunosuppressive pathways important for the regulation of anticancer immunity and to discover new immune activating strategies with the objectives to isolate subgroups of GBMs that could benefit from an immunotherapy approach. To achieve this goal, GBM tumor samples and a blood sample will be collected during the initial tumor resection.

The sites involved in the recruitment of the patients will be the neurosurgical teams in Brussel, Dijon, Nantes and Padova.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma

NCT03687099

Glioblastoma

COMPLETED

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma

NCT02866747

Glioblastoma

COMPLETED PHASE1/PHASE2

Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme

NCT01464177

Recurrent Glioblastoma Multiforme

COMPLETED PHASE2

Glioblastoma and Individualized Therapies

NCT05356312

Glioma, Malignant

AVAILABLE

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

NCT01268566

Glioblastoma Multiforme

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective :

The primary objective is to determine for each of the 3 molecular subtypes of glioblastoma the predictive performance on 1-year overall survival of in situ immune parameters

Secondary objectives :

To identify the best combination of in vivo immune parameters that is predictive of 1-year overall survival To determine the impact of immune parameters on overall survival Create a collection of biological samples

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with newly diagnosed, brain tumor
2. Gross or near total resection of the contrast-enhancing tumor mass decides by the neurosurgeron.
3. Subjects ≥18 and ≤75 years of age at surgery
4. Patients must be able to understand and sign the informed consent documents indicating that they are aware of the investigational nature of this study.
5. Confirmation of the diagnosis of grade IV GBM by the local pathologist with an independent neuropathologist who will review this diagnosis
6. Primary therapy must consist of surgical resection with the intent for a gross or near total resection of the contrast-enhancing tumor mass, followed by conventional external beam radiation therapy and concurrent temozolomide chemotherapy.
7. Tumor biopsy for biological analysis has to be performed before using ultrasonic surgery

Exclusion Criteria

1. Patient with other type of primary brain tumor or metastases
2. Patients with only biopsy performed for the diagnosis
3. Subjects under guardianship, curatorship or judicial protection
4. Female subjects who are pregnant or breast-feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No